


RESEARCH

Open Access



Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Melanoma brain metastases prognostic score

Jana Schaule^{1,2*} , Stephanie G. C. Kroeze^{1†}, Oliver Blanck^{2,3}, Susanne Stera⁴, Klaus H. Kahl⁵, Falk Roeder⁶, Stephanie E. Combs^{7,8,9}, David Kaul¹⁰, An Claes¹¹, Markus M. Schymalla¹², Sonja Adebahr^{13,14,15}, Franziska Eckert¹⁶, Fabian Lohaus^{15,17,18}, Nasrin Abbasi-Senger¹⁹, Guido Henke²⁰, Marcella Szuecs²¹, Michael Geier²², Nora Sundahl²³, Daniel Buergy²⁴, Reinhard Dummer²⁵ and Matthias Guckenberger¹

Abstract

Background: Melanoma patients frequently develop brain metastases. The most widely used score to predict survival is the molGPA based on a mixed treatment of stereotactic radiotherapy (SRT) and whole brain radiotherapy (WBRT). In addition, systemic therapy was not considered. We therefore aimed to evaluate the performance of the molGPA score in patients homogeneously treated with SRT and concurrent targeted therapy or immunotherapy (TT/IT).

Methods: This retrospective analysis is based on an international multicenter database (TOaSTT) of melanoma patients treated with TT/IT and concurrent (≤ 30 days) SRT for brain metastases between May 2011 and May 2018. Overall survival (OS) was studied using Kaplan-Meier survival curves and log-rank testing. Uni- and multivariate analysis was performed to analyze prognostic factors for OS.

Results: One hundred ten patients were analyzed. 61, 31 and 8% were treated with IT, TT and with a simultaneous combination, respectively. A median of two brain metastases were treated per patient. After a median follow-up of 8 months, median OS was 8.4 months (0–40 months). The molGPA score was not associated with OS. Instead, cumulative brain metastases volume, timing of metastases (syn- vs. metachronous) and systemic therapy with concurrent IT vs. TT influenced OS significantly. Based on these parameters, the VTS score (volume-timing-systemic therapy) was established that stratified patients into three groups with a median OS of 5.1, 18.9 and 34.5 months, respectively ($p = 0.001$ and 0.03).

(Continued on next page)

* Correspondence: jana.schaule@uk-erlangen.de

[†]Jana Schaule and Stephanie G. C. Kroeze contributed equally to this work.

¹Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland

²Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusion: The molGPA score was not useful for this cohort of melanoma patients undergoing local therapy for brain metastases taking into account systemic TT/IT. For these patients, we propose a prognostic VTS score, which needs to be validated prospectively.

Keywords: molGPA, Melanoma, Stereotactic, Brain metastases, Immunotherapy, Targeted therapy

Background

About 40–60% of melanoma patients will develop brain metastases during the course of their disease, which contributes to a worse prognosis and quality of life [1]. Median overall survival (OS) from presentation of brain metastases to death used to be only 3 months [2]. Recent developments in the fields of targeted- and immunotherapy (TT/IT), as well as the now widespread use of stereotactic radiosurgery (single fraction, SRS) and stereotactic radiotherapy (fractionated stereotactic radiotherapy, SRT) have significantly improved survival [3]. In the following, the term SRT will be used for both, single- and multi-fraction stereotactic radiotherapy. Despite response rates of melanoma brain metastases of up to 40–60% to IT and TT, presence of brain metastases remains a limiting factor for survival [4–8], indicating that IT/TT as monotherapy is often not sufficient. SRT is effective in controlling brain metastases, with the advantage of preserving cognitive function compared to whole brain radiotherapy (WBRT) [9–11]. For a limited number of up to four brain metastases, SRT without WBRT is now the preferred treatment option [12]. However, evidence is emerging that not number, but the volume of brain metastases determines whether patients should receive SRT [10]. In the rapidly changing setting of treatment opportunities for melanoma patients it remains unclear, which patients benefit most from local treatment and there is a need for a reliable prognostic score to tailor treatment.

Several scores have been developed aiming to predict survival in patients with brain metastases [13–15]. However, caution is required as these scores have not been established or validated in patients treated with combined SRT and TT/IT. In 2010, Sperduto et al. presented a refined version of the Graded Prognostic Assessment (GPA) focusing on melanoma patients (ds-GPA) [16]. Karnofsky performance status (KPS) and number of brain metastases were identified as prognostic factors for OS. Recently, the group updated the score in the light of new molecular markers, named molGPA score [17]. In addition to the above-mentioned factors, age, BRAF-mutational status and presence or absence of extracranial metastases were added as prognostic markers. The score is four-tiered as its predecessor and reflects the success of the advances in treatment by markedly prolonged median OS as compared to the ds-GPA [17]. However,

radiation treatment consisted of a multitude of different treatment regimens including surgery + SRT/WBRT, WBRT +/- SRT, or SRT alone. Furthermore, the score did not take into account whether and what systemic treatment these patients received as background to local treatment. In the only study to date that validated the molGPA score, 70% of patients received WBRT and concurrent systemic therapy was likewise not recorded [18]. Other available scores have been shown to underestimate OS as these were all developed before widespread implementation of TT/IT [19]. Two studies have aimed to validate prognostic scores in TT/IT-treated patient cohorts that received concomitant SRT to date, albeit omitting the most widely used molGPA score [20, 21]. Hence, this study aims to validate the molGPA score in a cohort of patients homogeneously treated with SRT and concurrent TT/IT to depict patterns of care of modern melanoma treatment.

Methods

A retrospective international multicenter registry study (TOaSTT) was established to collect data on patients receiving SRT (delivery of up to 10 high-dose stereotactic radiation fractions) with concurrent targeted- or immunotherapy. Ethics approval was obtained by the lead ethics committee in Zurich (BASEC-Nr. 2016–01807) and from all participating centers at their local ethics committees. For sub-analysis of melanoma patients with brain metastases, patients meeting the following criteria were included: ≥ 18 years of age, histopathologically confirmed diagnosis of melanoma with synchronous or metachronous (> 6 months after first diagnosis) brain metastases, patients receiving SRT of any number of cerebral metastasis and concurrent treatment with any type of the following targeted drugs: antibodies and tyrosine kinase inhibitors (targeted therapies, TT) and immune-checkpoint inhibitors (immunotherapy, IT). “Concurrent” was defined as application of the respective drug within 30 days prior or after SRT. SRT was defined as delivery of single or fractionated large dose irradiation fractions ranging from 1×18 Gy to 1×21 Gy for SRS or from 5×5 Gy to 6×5 Gy for SRT; Patients treated with linac-based SRT, robotic-SRT (Cyberknife) as well as Gammaknife were eligible. Patients receiving concurrent whole brain radiotherapy (WBRT) were excluded as well as melanoma patients in the database that

only received stereotactic radiotherapy extracranially. Patients were included irrespective of prior treatment regimens.

Overall survival (OS) was defined as time of start of SRT to time of death, living patients were censored at the date of last follow-up. In the case of multiple cerebral stereotactic irradiations, OS was calculated from start of last stereotactic treatment.

The score by Sperduto et al. was applied and groups were formed as described in the original publication awarding points for age, KPS, extracranial metastases, BRAF-status and number of brain metastases [17]. After performing uni- and multivariate analyses for patient-, tumor- and treatment factors associated with OS, we established a new prognostic score using factors of statistical significance.

Descriptive statistical analysis was performed with SPSS v25.0 statistic software package (IBM Corp., Armonk, NY, USA). The Kaplan-Meier method followed by log-rank analysis for comparison of subgroups was used to evaluate OS. Univariate and multivariate Cox regression analysis (Enter method) was performed to identify independent variables for OS. Chi-square test was used to compare differences between two independent groups. A *p*-value of less than 0.05 was deemed statistically significant.

Results

Patient and treatment characteristics

Patient and treatment characteristics are shown in Table 1.

One hundred ten patients were eligible for sub-analysis from the TOaSTT database. Median age at time of radiation was 59.4 years (25–82 years). The large majority of patients had a good performance status of ECOG 0–1 (93.6%). The median number of SRT-treated brain metastases was 2 (1–30). Forty-seven patients had a single metastasis, 53 had 2–4 metastases and 10 patients had > 4 brain metastases. The large majority of patients had extracranial metastases at time of cerebral SRT (83 patients; 75.5%), while only 27 patients (24.5%) suffered from exclusively cerebral disease. The median cumulative brain metastases volume was 1.5 cc ranging from 0.05–24.5 cc.

Fifty-seven (48.2%) patients harbored BRAF-mutations, 53 (51.8%) did not or it was unknown.

No Patients were treatment-naïve: 92% had received surgery (mostly for the primary tumor), 19% had received conventional immunotherapy (IL-2 or interferone), 23.6% had received conventionally fractionated radiotherapy, 2.7% had been treated with conventional chemotherapy, 38% had received previous SRT to the brain. In those cases, the last SRT was included in this analysis.

The majority of patients received concurrent IT alone (60.9%). Of those, 25.5% of patients received

Table 1 Patient and treatment characteristics

<i>n</i> = 110 patients	Median / <i>n</i> (% / range)
Age	59.4 (25–82)
Sex	
Male	64 (58.2)
Female	44 (44.0)
ECOG	
0	77 (70.0)
1	26 (23.6)
2	6 (5.5)
3	1 (0.9)
Number of brain metastases	median: 2 (1–30)
1	47 (42.7)
2–4	53 (48.1)
> 4	10 (9.0)
BRAF status	
positive	57 (48.2)
negative/unknown	46 (41.8) / 7 (6.3)
extracranial metastases	
yes	83 (75.5)
no	27 (24.5)
volume of brain metastases	
≥ 1.5 cc	55 (50.0) 1.5–24.54 cc
< 1.5 cc	55 (50.0) 0.05–1.4 cc
RT regimen	
SRS	95 (86.4)
SRT	15 (13.6)
Concomitant systemic therapy	
IT	67 (60.9)
TT	34 (30.9)
combination	9 (8.2)

Abbreviations: *SRS* Stereotactic radiosurgery, *SRT* Stereotactic radiotherapy, *IT* Immunotherapy, *TT* Targeted therapy

pembrolizumab, 16.3% ipilimumab, 12.7% nivolumab, the remaining 8% were treated with combinations of IT. Of all patients, 30.9% were treated with targeted therapy alone: Dabrafenib/trametinib was administered in 9% of cases, 8% received vemurafenib. The remaining nine patients received BRAF and/or MEK inhibitors (dabrafenib, binimetinib, trametinib, vemurafenib/cobimetinib, vemurafenib/osimertinib, encorafenib/binimetinib). Nine patients were treated with a combination of IT and TT. TT/IT was paused during SRT in 47% of patients. It was paused a median of 5 days (1–28 days) before SRT and restarted a median of 7 days (1–25 days) after SRS/SRT. Total median pause length was 14 days (1–29 days). In 49% of patients, TT/IT was not paused during SRT, data was missing for four patients. Patients treated with SRS

received a median of 20 Gy in one fraction ($n = 95$; range 18–21 Gy). Patients treated with SRT received 25–30 Gy total dose ($n = 15$; regimens varied between 5x5 Gy, 6x5 Gy or 5x6 Gy). Patients were treated with c-arm-based SRT with linear accelerators, robotic-based SRT (CyberKnife, Accuray, Sunnyvale, USA) as well as Gamma Knife (Elekta, Stockholm, Sweden). Median follow-up was 8 months (0–39 months) and median OS was 8.4 months (0–40 months).

Survival analysis by molGPA score factors

The prognostic factors of the molGPA score were analyzed. These are age, performance status, presence of extracranial disease, BRAF-status, and the number of brain metastases: OS between patients older or younger than 70 years did not differ ($p = 0.98$). Performance status did influence survival on univariate, but not on multivariate analysis (Table 2).

Patients with extracranial disease had a significantly worse OS compared to patients without extracranial disease in univariate analysis ($p = 0.02$) but not on multivariate analysis. Patients harboring BRAF-mutations had a worse OS compared to patients with an unknown or no BRAF-mutation ($p = 0.02$). Median OS in the patient group with BRAF-mutations was 5.4 months whereas median OS for BRAF-wild type patients (or with an unknown BRAF-status) was 10.7 months ($p = 0.001$). Importantly, the ECOG performance status did not differ between the BRAF positive and negative/unknown groups ($p = 0.5$). The number of SRT-treated brain metastases did not influence OS ($p = 0.29$) (1 vs. 2–4 metastases $p = 0.12$, 1 vs. >4 metastases $p = 0.07$; 2–4 vs >4 metastases $p = 0.68$).

Univariate analysis was additionally performed for cumulative brain metastases volume, timing of metastases (syn- vs. metachronous), type of systemic therapy (IT vs. no IT) and whether other metastases were controlled at time of SRT. In contrast to the number of brain metastases, OS was significantly associated with the cumulative brain metastases volume: patients with a cumulative brain metastases volume of < 1.5 cc had a median OS of 15.5 months, while the median OS for ≥ 1.5 cc brain metastases volume was 6.1 months ($p = 0.02$). On multivariate analysis, only cumulative brain metastases volume, timing of metastases and type of systemic treatment remained statistically significant (Table 2).

Application of the molGPA score and the VTS score

The molGPA score was applied to the cohort as described by the authors to estimate survival. Median OS was 4.8, 8.8, 15.0 and 15.5 months for the four groups with 0–1 points, 1.5–2 points, 2.5–3 point and 3.5–4 points, respectively. The score did not differentiate between the four groups well (log-rank across strata $p = 0.1$, Fig. 1a).

Based on the findings of the analysis, a different score, named the VTS score was established, where cumulative

brain metastasis volume, timing of metastases and type of systemic treatment were included as described above (Tables 3 and 4).

The groups were formed as described in a three-tiered manner. The VTS score was significantly associated with OS ($p < 0.0001$, Fig. 1b) with a median OS in the three groups of 5.1, 18.9 and 34.5 months, respectively.

When analyzing the sensitivity and specificity of the two scores to predict survival of patients at 6 months, the molGPA score did not show the capacity to predict survival, whereas the VTS score improved the prediction significantly. Hence, in a cohort of patients treated homogeneously with concurrent IT/TT and SRT, other factors than those informing the molGPA score may be of improved prognostic power (Fig. 2).

Discussion

To our knowledge, this is the first study attempting to validate the molGPA score in a cohort of melanoma patients with brain metastases, which was homogeneously treated with concurrent SRT and targeted- or immunotherapy. As these treatment combinations are rapidly implemented in routine practice, it is crucial to validate this score or develop more appropriate ones for this patient cohort. Using the measures proposed by Sperduto and colleagues [17], we were unable to validate the molGPA score. However, when using the factors cumulative brain metastasis volume, timing of brain metastases development and type of systemic treatment, survival was stratified in a statistically significant manner. On analysis using the receiver-operating-curve for the binary endpoint of 6-months-OS, the VTS score outperformed the molGPA with an AUC of 0.74 vs. 0.53.

Concurrent systemic treatment and SRT

Retrospective studies have investigated concurrent treatment of TT/IT and SRT in melanoma patients to date. Median OS was 7.5 months for concomitant CTLA-4-inhibitors, 17.8 months for concomitant BRAF-inhibitors and 20.4 months for concomitant anti-PD-1 treatment in a retrospective study of 108 melanoma patients receiving SRT for brain metastases (notably, 40% of patients received an additional WBRT) [22]. Gaudy-Marqueste et al. treated all brain metastases upfront with SRT followed by IT/TT. The cohort of 179 patients showed a median OS of 10.9 months [3]. Recently, 80 patients treated with concurrent ipilimumab or nivolumab and SRT to melanoma brain metastases were evaluated retrospectively for progression-free survival, OS and toxicity profile [23]. The OS times in the present study are in line with these studies.

In our cohort, treatment with immunotherapy was a factor positively associated with OS compared to concomitant use of targeted therapy. Only two prospective phase I studies are available at the moment evaluating the safety of concurrent SRT and nivolumab and ipilimumab, respectively [24, 25]. It

Table 2 Uni- and multivariate analysis (Cox regression, Enter method)

	n	Univariate HR (death) (95% CI)	P-value	Multivariate Enter HR (death) (95% CI)	P-value
Age^a					
< 70	82	0.99 (0.56–1.76)	0.98	0.76 (0.38–1.5)	0.43
≥ 70	27				
ECOG^a					
0	77	0.46 (0.27–0.77)	0.002	0.68 (0.39–1.19)	0.18
> 0	33				
BRAF^a					
Mutated	56	0.56 (0.34–0.93)	0.02	0.58 (0.32–1.05)	0.07
Wild type/unknown	53				
Number of brain metastases^a					
1	47	1.25 (0.85–1.82)	0.29	1.5 (0.425–4.98)	0.30
2–4	52				
> 4	10				
Extracranial metastases^a					
present	82	0.42 (0.56–1.76)	0.02	1.35 (0.37–4.98)	0.65
absent	27				
Brain metastases volume					
< 1.5 cc	54	0.56 (0.34–0.94)	0.03	0.54 (0.29–0.96)	0.04
≥ 1.5 cc	55				
Timing					
Synchronous	25	1.84 (1.05–3.24)	0.03	2.43 (1.24–4.75)	0.01
metachronous	84				
Systemic therapy					
IT	67	1.99 (0.37–8.48)	0.001	3.0 (0.98–9.26)	0.005
IT	34				
combination	8				
Other metastases controlled					
No	38	0.25 (0.01–1.97)	0.001	0.15 (0.01–12.18)	0.78
yes	34				
mixed	17				
no other metastases	19				

Abbreviations: HR Hazard ratio, CI Confidence interval; ^a = factors in the original molGPA score

has been hypothesized that SRT has the propensity to synergize with IT through five factors: 1) inducing immunogenic cell death by generating antigens 2) promoting antigen presentation on MHC I molecules enhancing the tumor cell killing through CD8 cytotoxic T-cells, 3) increasing blood-brain-barrier-permeability, 4) inducing chemokines that help overcome T-cell exclusion from the metastases and 5) through the rare abscopal effect [26–28]. A retrospective analysis of 395 patients with advanced melanoma in Switzerland likewise showed an improved median OS for patients receiving IT compared to TT (16.7 months vs. 11.2 months) [29]. However, only few prospectively collected

datasets have retrospectively investigated this potential synergy to date [24, 30, 31].

It currently remains unclear whether BRAF-mutated patients should receive TT or IT as first line therapy. It has been suggested that the type of BRAF-mutation (V600E vs. V600K) influences treatment response: The V600E mutation is more prone to responding to TT, while V600K-mutated tumors typically employ a higher tumor mutational burden and respond better to IT [32]. In this study, DNA-expression profiles to detect these differences were not available but should be investigated in the future to tailor treatment. There are multiple




Fig. 1 Kaplan-Meier curves comparing (a) the molGPA score with (b) the VTS score including cumulative brain metastases volume, timing of metastases, cumulative brain metastases volume and concomitant systemic treatment

Table 3 Survival of patients grouped by the VTS score

VTS score	n = 110	median OS (months)	logrank pairwise
0-1	46	5.1	vs. 1.5: 0.001 vs. 2: 0.0001
1.5	36	18.9	vs. 2: 0.03
2	28	34.5	

Abbreviations: VTS Volume-timing-systemic therapy, OS Overall survival

trials investigating the IT-TT combination treatment for BRAF-mutated melanoma patients showing overall response rates of up to 100%, albeit with 22% of patients discontinuing treatment due to toxicity (COMBI-I trial).

BRAF-mutation associated with worse OS

It was surprising that the BRAF-mutated patients in our cohort had a significantly worse OS than BRAF-wildtype patients. This might be explained by the effects of IT:

Table 4 Awarded points for VTS score

	0 points	0.5 points	1 point
Cumulative brain metastases volume	> 1.5 cc	< 1.5 cc	
Timing	synchronous	metachronous	
Systemic treatment	targeted therapy		immunotherapy

patients might have received IT at an earlier time point which then achieved improved OS [3]. Additionally, it has been acknowledged, that the timing of IT/TT and SRT is crucial [12, 33]. Recently, the immunomodulatory effects of SRT has been discussed in the literature leading to synergistic effects of the combined treatment as discussed above that might also be reflected in our finding [28, 34]. In the original molGPA study, BRAF-status was divided into three groups: positive, negative and unknown; whereby the unknown status (29% of patients) yielded the highest hazard ratio (1.94 vs 1.3 for negative and 1.0 for positive); nevertheless, negative and unknown were awarded 0 points in the score, raising doubts about the strength of prognostic value of this factor. In contrast, our data was very complete regarding BRAF-mutational status: the BRAF-status was unknown for only 7 patients.

The cumulative brain metastases volume factor


The first prognostic score index for radiosurgery (SIR) for brain metastases treated with SRT (including 10 melanoma patients; 15.3%) already included a volume factor stratifying by the largest irradiated lesion in three groups (< 5 cc, 5-13 cc and > 13 cc) [35]. SIR also considered the number of brain metastases. By using the cumulative brain metastases volume, parts of both factors are combined. A more recent evaluation of multiple prognostic scores (omitting the most recent molGPA score) by Badakhshi et al. had shown the cumulative brain metastases volume to be of importance. However, while yielding the highest level of statistical

significance on univariate analysis, cumulative brain metastases volume did not remain a statistically significant prognostic factor on multivariate analysis. The authors likewise stratified patients by smaller or larger than median cumulative brain metastases volume, which was similar to the median cumulative brain metastases volume in this study (2.47 cc) [20]. In their cohort of 80 patients, only 8.8% of patients received concurrent TT/IT. An evaluation of prognostic scores in 66 melanoma patients treated with SRT-only for brain metastases further supports the hypothesis that cumulative brain metastases volume contains more prognostic power compared to the mere number: on multivariate analysis, age > 60 years, performance status $\leq 80\%$, and notably, cumulative brain metastases volume > 2 cc was associated with worse OS, while number of brain metastases was not [36].

Of note, the authors of the molGPA score had investigated volume of brain metastases, although merely for SRS-only treated patients in their cohort (56%). It is not reported, whether this was the cumulative volume. Additionally, the brain metastases volume factor was applied to the entire cohort, albeit 25% of patients received WBRT, which could explain why this factor was not statistically significant for survival of the entire cohort [17].

Limitations

Limitations of this study include its retrospective character, the small number of patients compared to the original molGPA publication, and the utilization of the



ECOG score rather than the smaller scaled KPS. In the future, the newly developed VTS score needs to be externally validated. Notably, only 3.6% of patients received concurrent ipilimumab/nivolumab as systemic treatment with SRT, which is the standard of care treatment as of today [5, 6], which may be due to the recruitment time between 2011 and 2018. Combinations of BRAFi and MEKi were applied in 16.3% of cases, a standard TT-treatment for BRAF-mutated cutaneous melanoma according to ESMO guidelines [37]. FFig.

Conclusion

In conclusion, this study shows for the first time, that the molGPA score has to be used with caution for the rapidly growing cohort of melanoma patients treated with SRT concurrent with immuno- or targeted therapies for brain metastases. Factors such as cumulative brain metastasis volume, timing of metastases and type of systemic treatment should be taken into account in this cohort. In the future, timing of TT/IT and SRT should be investigated further and the VTS score should be validated to enrich the clinical decision-making tool enabling physicians to make the best decisions regarding treatment of brain metastases for their melanoma patients.

Abbreviations

AUC: Area under curve; ECOG: Eastern cooperative oncology group; molGPA: molecular graded prognostic assessment; IT: Immunotherapy; KPS: Karnofsky performance score; OS: Overall survival; SRT: Stereotactic radiotherapy; SRS: Stereotactic radiosurgery; TT: Targeted therapy; VTS: Volume – timing – systemic therapy; WBRT: Whole brain radiotherapy

Acknowledgements

The authors would like to thank Corinna Fritz, MD and Silvia Duschek, cand. Med. for supporting the set-up and maintenance of the database.

Authors' contributions

JS: Conceptualization, formal analysis, lead writing: original draft, SGCK: funding and ethics acquisition, data curation, writing review and editing. All others: data curation, review and editing, RD: review and editing, MG: conceptualization, writing review and editing. The authors read and approved the final manuscript.

Authors' information

The TOaSTT study group.

Funding

This work was partially funded by Varian Medical Systems.

Availability of data and materials

The dataset(s) supporting the conclusions of this article is (are) included within the article (and its additional file(s)).

Ethics approval and consent to participate

Ethics approval was obtained by the lead ethics committee in Zurich (BASEC-Nr. 2016–01807) and from all participating centers at their local ethics committees. All patients signed consent forms.

Consent for publication

NA

Competing interests

NS: travel grants from Merck Sharpe & Dohme, Astellas, Bayer and Bristol-Myers-Squibb. DB reports personal fees from Siemens AG, personal fees from NB Capital Research GmbH, personal fees from NB Capital ApS, personal fees from b.e. Imaging GmbH outside the submitted work. MS: remuneration for lectures from Merck Serono and AstraZeneca. All other authors declare no conflicts of interest.

Author details

¹Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. ²Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany. ³University Medical Center Schleswig-Holstein, Kiel, Germany. ⁴Department of Radiation Oncology, University Hospital Frankfurt, Frankfurt, Germany. ⁵Department of Radiation Oncology, Universitätsklinikum Augsburg, Augsburg, Germany. ⁶Department of Radiation Oncology, University Hospital Munich, Munich, Germany. ⁷Department of Radiation Oncology, Technical University Munich (TUM), Munich, Germany. ⁸Institute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMZ), Oberschleißheim, Germany. ⁹German Cancer Consortium, Partner Site Munich, Munich, Germany. ¹⁰Department of Radiation Oncology, Charité-University Hospital Berlin, Berlin, Germany. ¹¹Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. ¹²Department of Radiation Oncology, Philipps-University Marburg, Marburg, Germany. ¹³Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Breisgau, Germany. ¹⁴German Cancer Consortium, Partner Site Freiburg, Freiburg, Germany. ¹⁵German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁶Department of Radiation Oncology, Eberhard Karls Universität Tübingen, Tübingen, Germany. ¹⁷Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. ¹⁸German Cancer Consortium, Partner Site Dresden, Dresden, Germany. ¹⁹Department of Radiation Oncology, University Hospital Jena, Jena, Germany. ²⁰Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. ²¹Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany. ²²Department of Radiation Oncology, Ordensklinikum Linz, Linz, Austria. ²³Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. ²⁴Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ²⁵Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

Received: 12 April 2020 Accepted: 1 May 2020

Published online: 01 June 2020

References

- Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. *Am J Surg*. 1978;135: 807–10.
- Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. *J Neurosurg*. 1998;88:11–20.
- Gaudy-Marqueste C, Dussouil AS, Carron R, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. *Eur J Cancer*. 2017;84: 44–54.
- Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, et al. Clinical Management of Multiple Melanoma Brain Metastases: a systematic review. *JAMA Oncol*. 2015;1:668–76.
- Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol*. 2018;19:672–81.
- Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. *N Engl J Med*. 2018;379:722–30.
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol*. 2017;18: 863–73.
- Dummer R, Goldinger SM, Turtchi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAFV600 mutation-positive melanoma

- with symptomatic brain metastases: final results of an open-label pilot study. *Eur J Cancer*. 2014;50:611–21.
9. Kocher M, Soffiotti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. *J Clin Oncol*. 2011;29:134–41.
 10. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLKG0901): a multi-institutional prospective observational study. *Lancet Oncol*. 2014;15:387–95.
 11. Shultz DB, Modlin LA, Jayachandran P, et al. Repeat courses of stereotactic radiosurgery (SRS), deferring whole-brain irradiation, for new brain metastases after initial SRS. *Int J Radiat Oncol Biol Phys*. 2015;92:993–9.
 12. Rauschenberg R, Bruns J, Brütting J, et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. *Eur J Cancer*. 2019;110:11–20.
 13. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys*. 1997;37:745–51.
 14. Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. *J Neurosurg*. 2008;109(Suppl):77–86.
 15. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. *Int J Radiat Oncol Biol Phys*. 2008;70:510–4.
 16. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. *Int J Radiat Oncol Biol Phys*. 2010;77:655–61.
 17. Sperduto PW, Jiang W, Brown PD, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). *Radiat Oncol Biol*. 2017;99:812–6.
 18. Nieder C, Hintz M, Bilger A, Oehlke O, Grosu A. Validation of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). *J Clin Med Res*. 2018;10:178–81.
 19. Rice SR, Bentzen SM, Hanna A, et al. Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. *J Neuro-Oncol*. 2018;140:341–9.
 20. Badakhshi H, Engeling F, Budach V, Ghadjar P, Zschaek S, Kaul D. Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era? *Radiat Oncol*. 2018;13:1–6.
 21. Kano H, Morales-Restrepo A, Iyer A, Weiner GM, Mousavi SH, Kirkwood JM, et al. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. *J Neurosurg*. 2018;128:14–22.
 22. Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, et al. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. *Eur J Cancer*. 2017;75:169–78.
 23. Minniti G, Anzellini D, Reverberi C, Cappellini GCA, Marchetti L, Bianciardi F, et al. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. *J Immunother Cancer*. 2019;7:102.
 24. Ahmed KA, Stallworth DG, Kim Y, Johnstone PAS, Harrison LB, Caudell JJ, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. *Ann Oncol*. 2016. <https://doi.org/10.1093/annonc/mdv622>.
 25. Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 study of Ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. *Int J Radiat Oncol*. 2017;99:22–30.
 26. Twyman-Saint Victor C, Rech AJ, Maitly A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015;520:373–7.
 27. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the Abscopal effect in a patient with melanoma. *N Engl J Med*. 2012. <https://doi.org/10.1056/NEJMoa1112824>.
 28. Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. *Neuro-Oncology*. 2015;17:1312–21.
 29. Mangana J, Cheng PF, Kaufmann C, et al. Multicenter , real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. *Melanoma Res*. 2017;27:358–68.
 30. Knisely JPS, Yu JB, Flanigan J, Szoln M, Kluger HM, Chiang VLS. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. *J Neurosurg*. 2012;117:227–33.
 31. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. *Cancer Med*. 2013. <https://doi.org/10.1002/cam4.140>.
 32. Pires da Silva I, Wang KYX, Wilmott JS, et al. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K *BRAF* -mutant melanoma. *Clin Cancer Res*. 2019;25:1272–9.
 33. Stera S, Balermipas P, Blanck O, et al. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. *Melanoma Res*. 2019;29:187–95.
 34. Marciscano AE, Haimovitz-Friedman A, Lee P, et al. Immunomodulatory effects of stereotactic body radiation therapy (SBRT): preclinical insights and clinical opportunities. *Int J Radiat Oncol Biol Phys*. 2019. <https://doi.org/10.1016/j.ijrobp.2019.02.046>.
 35. Weltman E, Salvajoli JV, Brandt RA, de Moraes HR, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. *Int J Radiat Oncol Biol Phys*. 2000;46:1155–61.
 36. Likhacheva A, Pinnix CC, Parikh N, et al. Validation of recursive partitioning analysis and diagnosis-specific graded prognostic assessment in patients treated initially with radiosurgery alone. *J Neurosurg*. 2012;117(Suppl):38–44.
 37. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26:v126–32.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://www.biomedcentral.com/submissions)

